|
Welcome
|
|
23 May 2012
|
|
|
| home | my details | ISRCTN Register | mRCT | links | information | press |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
| [ ...Back to search results ] | [ Print-friendly version ] |
| The effects of epidermal growth factor receptor inhibition on pulmonary arterial hypertension associated with systemic sclerosis |
| ISRCTN | ISRCTN75611179 |
| ClinicalTrials.gov identifier | |
| Public title | The effects of epidermal growth factor receptor inhibition on pulmonary arterial hypertension associated with systemic sclerosis |
| Scientific title | |
| Acronym | N/A |
| Serial number at source | 155/2006 |
| Study hypothesis | As Epidermal Growth Factor Receptor (EGFR) plays a role in pathogenesis of both pulmonary arterial hypertension and systemic sclerosis, EGFR inhibition will lead to beneficial effects in disease course. |
| Lay summary | |
| Ethics approval | Approval received from the Medical Ethics Review Committee of VU University Medical Centre. |
| Study design | Phase II study, open-labelled trial |
| Countries of recruitment | Netherlands |
| Disease/condition/study domain | Sclerosis-associated Pulmonary Arterial Hypertension (SScPAH) |
| Participants - inclusion criteria |
A subject is eligible for inclusion in this study only if all of the following criteria apply:
1. Written informed consent 2. Systemic sclerosis 3. Pulmonary Arterial Hypertension (PAH) with a mean Pulmonary Arterial Pressure (PAP) of above 25 mmHg measured during rest 4. Pulmonary Vascular Resistance (PVR) above 300 dynes 5. Total Lung Capacity (TLC) more than 70% 6. New York Heart Association (NYHA) class III and/or six-Minute Walk Test (6-MWT) less than 80% predicted 7.Conventional PAH treatment and/or bosentan and/or sildenafil treatment 8. Stability on medication during the previous three months (defined as stable or decrease of 6-MWT after three months of treatment) |
| Participants - exclusion criteria |
A subject will be excluded from this study in case of the following criteria:
1. Left ventricular dysfunction 2. Valvular heart disease 3. Pericardial constriction 4. Wedge pressure more than or equal to 15 mmHg 5. Chronic thromboembolic pulmonary hypertension 6. Uncontrolled sleep apnea 7. History of malignancies 8. Overt right heart failure 9. History or presence of skin ulcerations 10. Women Of Child-Bearing potential (WOCB) who are unwilling or unable to use contraceptives 11. Sexually active fertile man not using effective birth control if their partners are WOCB 12. Severe abnormality of the cornea 13. Inadequate haematologic function defined by an absolute neutrophil count less than 1,500/mm^3, platelet count less than 80,000/mm^3 and haemoblobin level of less than 9 g/dL 14. Inadequate hepatic function defined by a total bilirubin level 1.5 times the Upper Limit of Normal (ULN) and ASpartate AminoTransferase (ASAT) levels 2.5 times ULN 15. Inadequate renal function defined by a serum creatinine level more than 1.5 times ULN (alternative: Cockroft less than 50 ml/min) 16. Substances that inhibit CYP3A4 activity, such as rifampicin, phenytoin, ketoconazole, itraconazole |
| Anticipated start date | 01/01/2007 |
| Anticipated end date | 01/01/2010 |
| Status of trial | Completed |
| Patient information material | |
| Target number of participants | 20 |
| Interventions | All participants will receive cetuximab at a loading dose of 400 mg/m^2 in week one, followed by a weekly dose of 250 mg/m^2 starting from week two, up to a total of 12 weeks. |
| Primary outcome measure(s) | Safety: recorded by assessment and documentation in the Case Report Form (CRF) file of adverse events and toxicity (physical examination [with special attention to skin toxicity], laboratory data) at pre-treatment, treatment visits (week one to 12), and follow-up (six months, 12 months). |
| Secondary outcome measure(s) | Efficacy: measured by effects on six minute walk test, stroke volume, changes in High Resolution Computed Tomography (HRCT), N-Terminal B-type Natriuretic Peptide (NT-pro-BNP). |
| Sources of funding | VU University Medical Center (The Netherlands) |
| Trial website | |
| Publications | |
| Contact name | Dr A Boonstra |
| Address |
VU University Medical Center
Department of Pulmonary Diseases P.O. Box 7057 |
| City/town | Amsterdam |
| Zip/Postcode | 1007 MB |
| Country | Netherlands |
| Tel | +31 (0)20 444 4782 |
| a.boonstra@vumc.nl | |
| Sponsor | VU University Medical Centre (The Netherlands) |
| Address | Van der Boechorststraat 7 |
| City/town | Amsterdam |
| Zip/Postcode | 1081 BT |
| Country | Netherlands |
| Sponsor website: | http://www.vumc.nl/english/#http://www.vumc.nl/english/ |
| Date applied | 01/02/2007 |
| Last edited | 06/02/2007 |
| Date ISRCTN assigned | 01/02/2007 |
|
|
|
|
|
| © 2012 ISRCTN unless otherwise stated. | |
|
|
|
|